← back to ranking

CVS · CVS Health Corporation

Medical - Healthcare Plans · mkt cap $114.2B · calls: Q1 FY2026 vs Q4 FY2025
59.0 conviction · conf-adj 59

conf 5/10 partial

enthusiasm:27.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:5 · business_impact:8 · disruption:0 · commitment:6 · confirmation:0

Enthusiasm latest 9 / prev 7 (rising)

CVS's AI thesis is rising: management moved from broad enterprise AI and interoperability language in Q4 FY2025 to an explicitly "AI native" Health100 platform and detailed Aetna use cases in Q1 FY2026. The most credible quantified impact is operational, especially prior authorization speed and standardization, while revenue, margin, and cost savings from AI remain unquantified. Management frames AI as both an efficiency tool and a consumer-engagement growth platform, but the P&L inflection remains qualitative.

GROUNDED NEXT-FY IMPACT vs CONSENSUS

Grounded on actual base — revenue $402.1B · net income $1.8B · net margin 0.4% · diluted EPS 1.39

These are next-fiscal-year annual uplift estimates, not next-quarter numbers.

Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: medium (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 5/10

ClaimFigureArithmeticNext-FY Rev %Next-FY EPS %
95%+ eligible prior auths approved <24h (Q1'26)
productivity · soft		more than 95%Operational throughput metric. No PA processing cost base, FTE count, or $ saving disclosed anywhere in the claims. Cannot compute after_tax_saving = saving_$*(1-0.21) without a saving_$. Faster auth ~ marginal admin-cost relief but unquantifiable from inputs.
80%+ eligible prior auths approved in real time
productivity · soft		over 80%Same process-efficiency metric as the 24h figure; no dollar saving base or baseline rate disclosed. No anchor to convert to net income.
88% of Aetna PA procedures standardized today
productivity · soft		88%Standardization share — operational, not a $ or volume base. No PA cost pool or per-procedure saving given to size opex savings.
Standardize most-common PAs = >50% of PA volume by year-end
productivity · soft		over 50% of PA volumePA 'volume' is given only as a percentage, never in $ or unit count. No base to translate 50% into a saving. Soft.
95% eligible PAs approved <24h (Q4'25)
productivity · soft		95%Restatement of the same operational throughput metric one quarter earlier; no incremental dollar base.
185M+ consumers engage across CVS Health yearly
engagement · soft		over 185 million consumersEngagement scale tied to the AI 'open engagement platform' (Health100). Implies ~$2,173 revenue per engaged consumer ($402.067B/185M), but no take-rate, ARPU, incremental consumers, or revenue-per-consumer lift disclosed. 185M is a reach number, not a sizable revenue driver. Soft.

Assumptions: Would-be defaults: incremental net margin = current 0.44% for any volume claim; 21% tax on any opex saving; phasing = next-FY (FY2026) portion only. None could be applied — no claim supplies a dollar revenue or dollar saving base, and no base appears anywhere across the claim set to borrow under the DISCLOSED-BASE rule. Current net income is positive ($1.768B) so the EPS-uplift guardrail is not triggered, but it is depressed (0.44% margin), which would make any real saving look large in % terms. Revenue base ($402B) is large, not small. All claims are adopter-side (AI applied to CVS's own prior-auth processing and member engagement); no AI capacity/compute/infrastructure is being sold, so supplier side = 0.

Top line: No quantifiable topline AI uplift can be derived. The only topline-tagged claim — 185M+ consumers on the AI engagement platform (Health100) — is a reach figure with no disclosed take-rate or revenue-per-consumer, so it cannot be mapped to a revenue line. Health100 itself is still pre-launch ('later this year'), with management explicitly deferring product/partnership revenue to 'coming quarters.' Aggregate est_rev_uplift_pct = null.

Bottom line: No quantifiable bottom-line AI uplift. The PA-automation metrics (95% <24h, 80% real-time, 88% standardized, >50% of PA volume targeted) are genuine operational improvements that plausibly lower Aetna's administrative cost, but management disclosed no PA processing cost pool, FTE count, or $ saving — so after_tax_saving = saving_$*(1-0.21) is uncomputable. Against a thin $1.768B net income base any real saving would screen large, which makes the absence of a disclosed figure the binding constraint. Aggregate est_eps_uplift_pct = null.

[impact n/m (all claims soft/unanchored)] Consensus already embeds a ~4.8x EPS recovery (current $1.39 -> FY2025 forward $6.67 -> FY2026 $7.39, +431.7%) and net income rising from $1.768B to $9.354B (+$7.586B, 5.3x), driven by margin normalization — none of it attributable to a quantified AI claim. Consensus revenue growth is modest (+1.8% FY25->26, +4.4% FY26->27, to $425.3B). Since the AI claims carry zero disclosed dollars, there is no measurable increment to test against this trajectory; the operational efficiencies are best treated as already inside the modeled margin recovery rather than as upside above it. No identifiable consensus gap to exploit.

MODEL CONSENSUS (impact)

partial

Full agreement on every claim, all null/soft, adopter-side, priced_in high, vs_analyst unclear. Only confidence differed; averaged to 5.

Conflicts reconciled
FieldOpus 4.8GPT-5.5
Rev uplift %––
EPS uplift %––
Priced inhighhigh
vs analystsunclearunclear
Confidence64
Top lineNo quantifiable topline AI uplift can be derived. The only topline-tagged claim — 185M+ consumers on the AI engagement platform (Health100) — is a reach figure with no disclosed take-rate or revenue-per-consumer, so it cannot be mapped to a revenue line. Health100 itself is still pre-launch ('later this year'), with management explicitly deferring product/partnership revenue to 'coming quarters.' Aggregate est_rev_uplift_pct = null.No quantified AI revenue uplift is disclosed. The 185M consumer engagement base implies $2,173.34 revenue per engaged consumer using $402.067B / 185M, but without incremental engagement or take-rate math, revenue uplift is null.
Bottom lineNo quantifiable bottom-line AI uplift. The PA-automation metrics (95% <24h, 80% real-time, 88% standardized, >50% of PA volume targeted) are genuine operational improvements that plausibly lower Aetna's administrative cost, but management disclosed no PA processing cost pool, FTE count, or $ saving — so after_tax_saving = saving_$*(1-0.21) is uncomputable. Against a thin $1.768B net income base any real saving would screen large, which makes the absence of a disclosed figure the binding constraint. Aggregate est_eps_uplift_pct = null.PA automation and standardization claims are directionally bottom-line positive, but 95%+ within 24 hours, 80%+ real-time, 88% standardized, and 50%+ PA-volume standardization lack a PA cost base or savings rate, so EPS uplift is null.
ReasoningConsensus already embeds a ~4.8x EPS recovery (current $1.39 -> FY2025 forward $6.67 -> FY2026 $7.39) and net income going from $1.768B to $9.35B (5.3x), driven by margin normalization — none of it attributable to a quantified AI claim. Consensus revenue growth is modest (+1.8% FY25->26, +4.4% FY26->27, to $425.3B). Since the AI claims carry zero disclosed dollars, there is no measurable increment to test against this trajectory; the operational efficiencies are best treated as already inside the modeled margin recovery rather than as upside above it. No identifiable consensus gap to exploit.Consensus already models net income rising from $1.768B current to $9.354B in FY2026, a +$7.586B increase, and EPS rising from $1.39 to $7.39487, a +431.7% increase. The disclosed AI claims add $0 of hard quantified uplift versus that consensus path because all claim-level impacts are unanchored.

Rows highlighted where the two models disagreed.

QUANTIFICATIONS
Eligible prior authorizations approved within 24 hours: more than 95% (Q1 FY2026 / current, bottomline)
“Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time.”
Eligible prior authorizations approved in real time: over 80% (Q1 FY2026 / current, bottomline)
“Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time.”
Standardized procedures for prior authorization: 88% (Q1 FY2026 / today, bottomline)
“Importantly, Aetna is well ahead of the industry standard with 88% of procedures standardized today.”
Most common prior authorizations targeted for standardization: over 50% of the PA volume (by the end of this year, bottomline)
“Over the past several months, we rallied and worked with key industry peers through AHIP to commit to standardize the services for the most common prior authorizations, which represent over 50% of the PA volume by the end of this year.”
Eligible prior authorizations approved within 24 hours: 95% (Q4 FY2025 / current, bottomline)
“Additionally, 95% of eligible prior authorizations are approved within 24 hours with many completed instantaneously.”
Consumer engagement scale for open engagement platform: over 185 million consumers (Q4 FY2025 / every year, topline)
“If you think about some of the things that Len said earlier, and David said, we have over 185 million consumers that engage with us across CVS Health every year.”
PAST (realized)
CURRENT (now)
FORWARD (guidance)
TRACK RECORD — PROMISE vs DELIVERY

56/100 track record   mixed  6 calls reviewed

CVS makes few hard-quantified AI promises and much of its AI talk is vague, but its concrete intelligent-automation commitments around prior-authorization (bundling expansion, 95%/24h approval) were consistently delivered and improved; bigger AI-platform bets (Health100, $20B transformation, 50% PA standardization by end-2026) remain too early, making the track record credible-but-thin.

Expand AI-driven bundled prior-authorization (one upfront approval) beyond cancer imaging to MSK/cardiology 'later this year' and other conditions — promised Q1 FY2025
delivered Delivered and kept expanding — Q4 FY2025 cited MSK and oncology bundles live, Q1 FY2026 added IVF combining medical + drug authorizations
Maintain intelligent-automation prior-auth performance: 95%+ of eligible PAs approved within 24 hours — promised Q1 FY2025
delivered Consistently restated and improved across calls — Q4 FY2025 and Q1 FY2026 reaffirmed 95% within 24h, with Q1 FY2026 adding 80%+ approved in real time
Standardize the most common prior authorizations representing over 50% of PA volume by end of 2026 (Aetna already 88% standardized) — promised Q1 FY2026
too-early Year-end 2026 milestone has not yet arrived (current date mid-2026); Aetna ahead at 88% but industry-wide target unproven
Launch Health100, an 'AI native' integrated consumer engagement platform, later in 2026 — promised Q1 FY2026
too-early Announced for later-2026 launch with no quantified adoption/financial target yet; timeframe not arrived
Invest $20B over the next decade in technology/emerging tech to make the healthcare experience 'unrecognizable in 10 years' — promised Q2 FY2025
too-early Long-dated, largely aspirational commitment with no near-term AI-specific deliverable to judge
PRICED-IN (REFINED)
MEDIUM

Est. revisions rising  ·  Fwd P/E 13.4  ·  EV/Sales 0.4x

AI claim maps to Pharmacy Revenue, Premiums, Front Store Revenue

Estimate signals lean rising: price targets have moved up from lastYearAvg 96 to lastQuarterAvg 103.58 to lastMonthAvg 105.1, while FY EPS estimates imply growth from 6.67 to 8.38 by 2027, even though rating counts are mostly stable. Valuation is not stretched for a mature healthcare company at 13.4x forward earnings and roughly 0.4x EV/sales, so the market is not paying a rich AI multiple. AI upside would most plausibly flow through Pharmacy Revenue and Premiums via automation, utilization management, claims, adherence, and cost efficiency. Because rising estimates make the thesis more priced-in but valuation remains reasonable, the refined verdict is medium.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
3Q4 FY20245Q1 FY20255Q2 FY20253Q3 FY20253Q4 FY20258Q1 FY2026

AI enthusiasm across 6 calls — trend ↗ rising

AI moved from broad technology mentions to real-time recommendations, then culminated in Health100 and enterprise-wide AI-enabled engagement and operations.

RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY

7/10 qualitative impact   material  medium-term · mixed evidence

Where AI matters: Aetna prior authorization, claims, member navigation, Health100 engagement platform

CVS has credible deployed AI in core healthcare operations, including more than 95% of eligible prior authorizations approved within 24 hours and over 80% in real time, which can improve admin cost, provider friction, and member experience. The broader Health100 and consumer-engagement thesis could be important across pharmacy, PBM, payer, and care navigation, but financial uplift remains undisclosed and partly pre-launch.

Caveats: No disclosed dollar savings, margin uplift, or revenue contribution from AI initiatives; Health100 is still pre-launch and may not convert reach into monetizable engagement; AI-enabled prior authorization could face regulatory, provider, or member backlash if perceived as denial automation; PBM and payer pricing models may face transparency pressure from AI-driven competitors or regulators

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

AI does not directly automate away CVS's core revenue model of pharmacy dispensing, PBM services, premiums, and healthcare access; it mostly improves workflow speed, utilization management, personalization, and service cost. There is some risk that AI transparency tools pressure PBM spreads or managed-care admin economics, but the regulated, networked, balance-sheet-heavy model is not structurally commoditized by AI alone.

OPTIONS / MARKET STRUCTURE

option liquidity: good

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $718M · beta 0.592 · px $89.50

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions flat, management language 7/10 committed.
INSIDERS selling 9 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) flat as of 2026-03-31: 155 new / 244 closed positions; 869 increased / 748 reduced; institutional ownership -2.49pp; -84 net 13F holders
MGMT LANGUAGE 7/10 committed Mostly firm ownership and present-tense deployment, with a dated launch, though strategic impact is partly framed as belief and opportunity.
commit “Later this year, we will be launching Health100, an AI native, state-of-the-art technology and service platform”
commit “AI has been deployed across CVS Health for years to improve our operations and to drive efficiencies.”
commit “It is already making it easier for our members to find the right providers and better navigate the system.”
VERBATIM AI QUOTES
“Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time.”
— J. Joyner, Q1 FY2026
“Later this year, we will be launching Health100, an AI native, state-of-the-art technology and service platform that allows for any payer, PBM, pharmacy or provider to seamlessly connect.”
— J. Joyner, Q1 FY2026
“We are focused on developing tech-forward solutions like Health100 because we believe the future of best-in-class health care companies will be powered by technology and AI.”
— J. Joyner, Q1 FY2026
“AI has been deployed across CVS Health for years to improve our operations and to drive efficiencies.”
— J. Joyner, Q1 FY2026
“But what we are most excited about and believe will have the biggest impact is AI's ability to improve consumer experiences, engagement and outcomes.”
— J. Joyner, Q1 FY2026
“It is already making it easier for our members to find the right providers and better navigate the system.”
— J. Joyner, Q1 FY2026
“We're enabling more personalized and exceptional care by empowering our pharmacists and clinicians with constantly improving insights.”
— J. Joyner, Q1 FY2026
“And we're accelerating our go-to-market strategies by using cutting-edge technology to develop deep consumer insights rapidly and at scale.”
— J. Joyner, Q1 FY2026
“So we've been investing in technology, AI, and have been driving some really nice results there.”
— Steven Nelson, Q1 FY2026
“One is really going deliberately at cost structure and improving efficiency.”
— Steven Nelson, Q1 FY2026
“Second bucket, which is really important, is it's improving the way we do our work.”
— Steven Nelson, Q1 FY2026
“The third bucket, which I'm also really excited about, I mentioned earlier is investing in the capabilities and better experience, more empowerment, better insights, better navigation for our members, things like Informed Choice, our Smart Compare products, Care Pathways, they all help our members be better consumers of health care.”
— Steven Nelson, Q1 FY2026
“Technology and AI are at the core of a lot of our businesses.”
— Prem Shah, Q1 FY2026
“And we're excited about how AI is going to help us accelerate and create unique solutions for members.”
— Prem Shah, Q1 FY2026
“This turnaround reflects our consistent investments in colleagues, technology and the consumer experience.”
— J. Joyner, Q4 FY2025
“We continue to focus on improving connectivity between our businesses, using technology to support greater interoperability and facilitate a common experience, which will ultimately make health care easier to navigate.”
— J. Joyner, Q4 FY2025
“Additionally, 95% of eligible prior authorizations are approved within 24 hours with many completed instantaneously.”
— J. Joyner, Q4 FY2025
“Finally, as we talked about at our Investor Day, we are using our deep consumer engagement and extensive technology to address the lack of interoperability within the health care system.”
— J. Joyner, Q4 FY2025
“AI, as you heard from us, it's being utilized across the enterprise, and we had the opportunity at Investor Day to highlight some of these examples and the way we're changing how we work, Erin, I think we're trying to change the experience we're able to provide in the health care system.”
— Brian Newman, Q4 FY2025
“So we're using AI to reimagine the health care experience, putting the consumer at the center and to ensure each business is best-in-class.”
— Brian Newman, Q4 FY2025
“It will both drive savings as well as accelerate growth.”
— Brian Newman, Q4 FY2025
“We strongly believe we can unlock the power of that connection with consumers and drive greater engagement in health care, improve the quality of health care and lower overall total cost of care.”
— Prem Shah, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Andrew Mok): With respect to AI, you're still reinvesting meaningfully across the enterprise, but you talked about the immense opportunity to drive systemic change. So one, can you help us understand the level and pace of AI investments you're making this year? And how we should think about the inflection point when AI shifts from net investment to net benefit on the P&L?
A: J. Joyner: "We see this really as an inflection point in our business." Steven Nelson: "For Aetna, we think about it in 3 buckets." "One is really going deliberately at cost structure and improving efficiency." "Second bucket, which is really important, is it's improving the way we do our work." "The third bucket, which I'm also really excited about, I mentioned earlier is investing in the capabilities and better experience, more empowerment, better insights, better navigation for our members." Prem Shah: "Technology and AI are at the core of a lot of our businesses."
Q (Q4 FY2025, Erin Wilson Wright): So on the technology investment side, you highlighted a lot of this at Investor Day, but can you break down a little bit more what some of those incremental investments are in 2026? Is there any sort of lumpiness to this that we should think about in terms of the quarterly progression of EPS and highlight some of those advancements or efficiencies gained from some of those investments?
A: Brian Newman: "AI, as you heard from us, it's being utilized across the enterprise" and "It will both drive savings as well as accelerate growth." Prem Shah: "Progress to date is performing well, and we believe we're uniquely positioned to create the next-generation of health care engagement."